RESUMO
Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and systemic flushing accompanied by extensive sterile pustules. The committee of the guidelines was founded as a collaborative project between the Japanese Dermatological Association and the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labour, and Welfare Research Project on Overcoming Intractable Diseases. The aim of the guidelines was to provide current information to aid in the treatment of patients with GPP in Japan. Its contents include the diagnostic and severity classification criteria for GPP, its pathogenesis, and recommendations for the treatment of GPP. Since there are few clinical trial data with high levels of evidence for this rare disease, recommendations by the committee are described in the present guidelines.
Assuntos
Fármacos Dermatológicos/uso terapêutico , Psoríase/terapia , Terapia Ultravioleta/normas , Ensaios Clínicos como Assunto , Terapia Combinada/métodos , Terapia Combinada/normas , Quimioterapia Combinada/métodos , Quimioterapia Combinada/normas , Humanos , Japão , Ceratolíticos/uso terapêutico , Psoríase/diagnóstico , Psoríase/patologia , Índice de Gravidade de Doença , Pele/patologia , Resultado do Tratamento , Terapia Ultravioleta/métodosAssuntos
Linfoma de Células B/terapia , Linfoma Cutâneo de Células T/terapia , Oncologia/normas , Medicina de Precisão/normas , Neoplasias Cutâneas/terapia , Administração Cutânea , Assistência ao Convalescente/métodos , Assistência ao Convalescente/normas , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/normas , Biomarcadores Tumorais/genética , Antígenos CD79/genética , Quimiorradioterapia/métodos , Procedimentos Cirúrgicos Dermatológicos/métodos , Procedimentos Cirúrgicos Dermatológicos/normas , Europa (Continente) , Humanos , Incidência , Linfoma de Células B/diagnóstico , Linfoma de Células B/epidemiologia , Linfoma de Células B/patologia , Linfoma Cutâneo de Células T/diagnóstico , Linfoma Cutâneo de Células T/epidemiologia , Linfoma Cutâneo de Células T/patologia , Oncologia/métodos , Fator 88 de Diferenciação Mieloide/genética , Estadiamento de Neoplasias , Pomadas , Medicina de Precisão/métodos , Pele/efeitos dos fármacos , Pele/patologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/patologia , Sociedades Médicas/normas , Sobrevivência , Resultado do Tratamento , Terapia Ultravioleta/métodos , Terapia Ultravioleta/normasAssuntos
Serviços de Assistência Domiciliar/normas , Teste de Materiais/normas , Terapia Ultravioleta/normas , Vitiligo/radioterapia , Calibragem/normas , Desenho de Equipamento/métodos , Desenho de Equipamento/normas , Humanos , Teste de Materiais/métodos , Radiometria/métodos , Radiometria/normas , Terapia Ultravioleta/métodos , Vitiligo/diagnósticoRESUMO
UV-based (PUVA and narrowband UVB) phototherapy is broadly and commonly used in the treatment of Cutaneous T-cell Lymphomas (CTCL), yet unfortunately, the evidence for the efficacy of these treatments is based only on case series or prospective but non-randomized studies. Therefore, no internationally approved guidelines exist and no standardization of schedules has been proposed. Recently, consensus guidelines have been published by the United States Cutaneous Lymphoma Consortium. The aim of this study was to review the biological and clinical evidences on PUVA and NB-UVB in CTCL and to critically evaluate acceptability and feasibility of these guidelines in the real-life setting from the perspective of the Cutaneous Lymphoma Task Force of the Italian Lymphoma Foundation (Fondazione Italiana Linfomi, FIL).
Assuntos
Micose Fungoide/radioterapia , Terapia Ultravioleta/métodos , Terapia Ultravioleta/normas , Protocolos Antineoplásicos , Humanos , Itália , Terapia PUVA/normas , Guias de Prática Clínica como Assunto , Síndrome de Sézary/radioterapiaRESUMO
BACKGROUND: Treatment of vitiligo with narrowband ultraviolet B light (NBUVB) is an important component of the current standard of care. However, there are no consistent guidelines regarding the dosing and administration of NBUVB in vitiligo, reflected by varied treatment practices around the world. OBJECTIVE: To create phototherapy recommendations to facilitate clinical management and identify areas requiring future research. METHODS: The Vitiligo Working Group (VWG) Phototherapy Committee addressed 19 questions regarding the administration of phototherapy over 3 conference calls. Members of the Photomedicine Society and a group of phototherapy experts were surveyed regarding their phototherapy practices. RESULTS: Based on comparison and analysis of survey results, expert opinion, and discussion held during conference calls, expert recommendations for the administration of NBUVB phototherapy in vitiligo were created. LIMITATIONS: There were several areas that required further research before final recommendations could be made. In addition, no standardized methodology was used during literature review and to assess the strength of evidence during the development of these recommendations. CONCLUSION: This set of expert recommendations by the VWG is based on the prescribing practices of phototherapy experts from around the world to create a unified, broadly applicable set of recommendations on the use of NBUVB in vitiligo.
Assuntos
Terapia Ultravioleta/métodos , Terapia Ultravioleta/normas , Vitiligo/radioterapia , Quimioterapia Adjuvante , Consenso , Humanos , Guias de Prática Clínica como Assunto , Dosagem Radioterapêutica/normas , Terapia Ultravioleta/efeitos adversosAssuntos
Conhecimentos, Atitudes e Prática em Saúde , Educação de Pacientes como Assunto/métodos , Segurança do Paciente/normas , Autocuidado , Terapia Ultravioleta/normas , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Melhoria de Qualidade , Dermatopatias/radioterapia , Inquéritos e Questionários , Comprimidos , EnsinoRESUMO
Psoriasis is a common, chronic immune-mediated inflammatory skin disorder that significantly impacts quality of life and has potential systemic complications. The majority of psoriatic patients have mild to moderate disease and are adequately controlled with topical medications. However, approximately 20% of patients have moderate-to-severe disease. Phototherapy has remained a mainstay option for patients with moderate-to-severe psoriasis resistant to topical treatments due to its efficacy, cost-effectiveness, and relative lack of side effects, in particular a lack of systemic immunosuppression seen with traditional and biologic systemic therapies. There are several well-established guidelines for phototherapy treatment of psoriasis proposed in the United States by the American Academy of Dermatology (AAD), in Europe by the European S3, and in the United Kingdom by the National Institute for Health and Care Excellence (NICE). The guidelines set by these groups are largely based on current evidence or expert panel consensus where evidence is lacking. This article reviews and compares the current recommendations of these guidelines for psoriasis phototherapy in regards to the initial clinical encounter, dosage, adverse reactions, and special considerations.
J Drugs Dermatol. 2016;15(8):995-1000.
Assuntos
Fototerapia/normas , Guias de Prática Clínica como Assunto/normas , Psoríase/terapia , Humanos , Terapia PUVA/métodos , Terapia PUVA/normas , Fototerapia/métodos , Psoríase/diagnóstico , Terapia Ultravioleta/métodos , Terapia Ultravioleta/normasRESUMO
Chronic itch (CI) is a frequent and sometimes tormenting symptom in many skin and systemic diseases. In systemic diseases, it mostly appears on primarily unaffected skin. As a sequelae of intense scratching, secondary skin lesions such as excoriations, scars, and prurigo nodularis may occur. Due to the lack of valid pathogenetic concepts and good clinical trials, the therapy of CI remains mostly symptomatic. In Europe almost all drugs used to treat CI are not approved for this indication. CI is frequent in patients with chronic kidney diseases in advanced stages. Gabapentin and pregabalin, anticonvulsants, and centrally acting calcium channel blockers have been shown to exert a profound effect in CI. Furthermore, UVB phototherapy has been proven to attenuate pruritus in uremic patients. Randomized controlled studies have recently shown that nalfurafine, a κ-opioid receptor agonist, is able to ameliorate itch in patients with uremic itch. In patients suffering from cholestatic itch, the anion exchange resin colestyramine and rifampicin are effective antipruritic drugs. Furthermore, µ-opioid receptor antagonists and sertraline may be used to alleviate CI in hepatic diseases. In refractory cases, naso-biliary drainage or albumin dialysis are effective invasive procedures. For the treatment of chronic itch in hematological diseases no controlled trials have been performed so far. The mainstay in these cases is to treat the underlying disease.
Assuntos
Antipruriginosos/administração & dosagem , Dermatologia/normas , Prurido/tratamento farmacológico , Prurido/prevenção & controle , Terapia Ultravioleta/métodos , Terapia Ultravioleta/normas , Antipruriginosos/normas , Doença Crônica , Relação Dose-Resposta a Droga , Europa (Continente) , Medicina Baseada em Evidências , Guias de Prática Clínica como AssuntoAssuntos
Monitoramento de Radiação/métodos , Raios Ultravioleta , Terapia Ultravioleta/normas , Calibragem , Governança Clínica , Desenho de Equipamento , Falha de Equipamento , Previsões , Humanos , Segurança do Paciente , Doses de Radiação , Exposição à Radiação/análise , Monitoramento de Radiação/instrumentação , Reprodutibilidade dos Testes , Pele/efeitos da radiação , Análise Espectral/instrumentação , Terapia Ultravioleta/instrumentação , Terapia Ultravioleta/tendênciasRESUMO
When treating psoriasis, various topical emollients exist that can affect the penetration of ultraviolet radiation in phototherapy. Compared with normal-appearing skin with a reflectance of 4% to 5%, psoriatic skin has higher reflectance as a result of its increased air-to-corneocyte interfaces. Studies have tested the effect of emollients on light penetration by assessing psoriatic plaque clearance, differences in minimal erythema dose, and physical properties of the emollient (eg, monochromatic protection factor and absorbance). Psoriatic plaque clearance was found to improve with serous (thin liquid)-based emollients (eg, Vaseline oil [Unilever, Blackfriars, London, UK], mineral oil, and glycerol), whereas clearance decreased with salicylic acid and viscous-based emollients (eg, petrolatum). Emollients with high ultraviolet absorbance properties increased minimal erythema dose, and those with low absorbance properties decreased minimal erythema dose. Interestingly, when a liquid emollient with a refractive index close to that of normal-appearing skin was applied, there was a net increase in light absorption, or a reduction in reflection that exceeded the emollient's innate ability to absorb light.
Assuntos
Emolientes/efeitos adversos , Fototerapia/métodos , Psoríase/terapia , Terapia Ultravioleta/métodos , Humanos , Fototerapia/normas , Refratometria , Terapia Ultravioleta/normasRESUMO
Use of ultraviolet radiation-emitting tanning devices has been classified as "carcinogenic to humans" (group 1) by the International Agency for Research on Cancer. Following this classification, the knowledge of typical ultraviolet emission levels from tanning devices can be of interest for evaluating their impact on health. In this work, the results of an extensive measurement campaign on artificial tanning appliances are presented. Ultraviolet emissions from 94 tanning appliances produced by 15 different manufacturers were characterized by onsite spectroradiometric measurements. The measured radiometric quantities were compared with reference values fixed in the European technical standard EN 60335-2-27 "Household and similar electrical appliances-Safety. Part 2: Particular requirements for appliances for skin exposure to ultraviolet and infrared radiation." Measurement results indicate that 88% of the examined appliances had ultraviolet emissions not compliant with the technical standard. Among the considered appliances, tanning devices equipped with low pressure lamps showed higher ultraviolet levels of effective irradiance and less compliance with standard requirements. In particular, UV emissions from 100% of low pressure appliances and from 78% of high pressure appliances exceeded the irradiance limit of 0.3 Wm set by the European technical standard.
Assuntos
Fidelidade a Diretrizes , Curtume/normas , Raios Ultravioleta , Terapia Ultravioleta/normas , União Europeia , Guias como Assunto , Humanos , Curtume/instrumentação , Terapia Ultravioleta/instrumentaçãoRESUMO
Narrow-band UVB (NB-UVB) is light over a very narrow band of wavelengths (around 311 nm) that is concentrated in the therapeutic range and minimally in the sunburn range. It has therefore become the phototherapy treatment of choice for skin diseases. The minimal erythema dose (MED) on canine skin for standardizing dosage schedules in NB-UVB treatment and histopathological analyses were performed in these dogs. In all 32 dogs tested, the MED ranged from 432 to 864 mJ/cm(2). There were no significant differences in MED among breeds, sex and age groups. Histopathology obtained from areas irradiated by MED showed only mild vascular dilatation. These findings might be valuable for the application of NB-UVB phototherapy to canine skin diseases.
Assuntos
Eritema/etiologia , Doses de Radiação , Pele/efeitos da radiação , Raios Ultravioleta , Terapia Ultravioleta/veterinária , Fatores Etários , Animais , Cães , Relação Dose-Resposta à Radiação , Valores de Referência , Fatores Sexuais , Pele/patologia , Terapia Ultravioleta/normasRESUMO
Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque-type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).
Assuntos
Fármacos Dermatológicos/administração & dosagem , Dermatologia/normas , Guias de Prática Clínica como Assunto , Psoríase/diagnóstico , Psoríase/terapia , Qualidade da Assistência à Saúde , Terapia Ultravioleta/normas , Administração Tópica , Adulto , HumanosRESUMO
Narrowband ultraviolet B phototherapy is an important treatment option for psoriasis and other skin diseases. When narrowband ultraviolet B phototherapy is initiated, one method involves determining the minimal erythema dose for each patient with the starting dose at 50% to 70% of the minimal erythema dose. An alternative method involves using the recommended narrowband ultraviolet B exposure dose based on a patient's Fitzpatrick skin type. When the recommended narrowband ultraviolet B exposure doses of separate publications are compared, alarming differences are found. These discrepancies not only create confusion but also suggest the risk of phototoxicity, or its opposite, namely the risk of suboptimal dosimetry. For these reasons, this article discusses possible explanations for the wide variation in dosimetry recommendations. To remedy the current situation, the authors advocate a national standard for the practice of phototherapy treatment with the guidelines of the United Kingdom as a possible model for emulation.
Assuntos
Fototerapia/normas , Guias de Prática Clínica como Assunto/normas , Radiometria/normas , Terapia Ultravioleta/normas , Relação Dose-Resposta à Radiação , Humanos , Avaliação das Necessidades , Dosagem Radioterapêutica , Dermatopatias/radioterapia , Reino UnidoRESUMO
BACKGROUND: Phototherapy, PUVA therapy and narrow-band UVB are recognised forms of first-line therapy for extensive and severe plaque psoriasis. Based on a systematic review of the medical literature, we propose a good practice guideline for the use of narrow-band UVB phototherapy in this indication. METHODS: We carried out a review of the literature published over the 20 years (1998 to 2009) in the online PubMed database. Our conclusions are based on the results of control studies or where these are absent, on a synthesis of the recommendations common practice approved by the experts of the French Society of Photodermatology. The levels of scientific proof given are based on the criteria defined by Sackett. RESULTS RECOMMENDATIONS: (1) Practical aspects. Irradiation cabins equipped with Philips TL01 tubes, either for monotherapy (42 tubes) or for combined therapy (21 UVB tubes and 21 UVA tubes), were to be certified (CE marking, ISO-DIN certification) and equipped with an accurate dosimetry system. Several valid and usable protocols exist. The indication was based on the severity and extent of the episode of psoriasis, the psychological consequences of the dermatosis, comparison of the benefit/risk ratios of the various available treatments, the ability of the patient to attend sessions (a vital factor in therapeutic compliance), the cumulative doses of UV from previous courses of treatment, and absence of contraindications, including the use of photosensitising medication. Informed consent was to be obtained from patients, who were given a validated information sheet (available at www.sfdermato.org). The study results and the value of maintenance therapy were not confirmed. (2) Adverse effects. The immediate adverse effects were generally of little consequence, with later effects alone posing problems. Because of the risk of induction of cataract, ocular protection must be used during sessions. In the absence of symptoms or known ocular disorder, prior ophthalmologic control is not considered necessary. The risk of skin cancer remains poorly defined, and this risk has not been clearly shown to be lower than with broad-spectrum UVB therapy or PUVA. The studies give no indication of the number of sessions after which therapy must be completely discontinued. In the absence of clear evaluation of oncogenic risk, it seems reasonable to set the maximum number of sessions of UVB TL01 phototherapy at 250 as with PUVA, and to include in this limit the total of all PUVA and TL01 phototherapy sessions for patients receiving both types of phototherapy (level of proof: B). In the absence of lesions requiring treatment in these areas, the face and male genital organs should be protected during treatment sessions. There is no currently available data concerning carcinogenic risk induced by TL01 in patients also on cyclosporine, methotrexate or biotherapies. In order to reduce risk and maintain patients' capacity to undergo further phototherapy sessions, we suggest (level of proof: A) the following measures: strict patient selection, use of combined synergistic therapies, annual examination of the skin and appendages of subjects receiving more than 150 phototherapy sessions, and the creation of nationally accessible patient phototherapy files. (3) Combined treatments. The purpose of such treatment is twofold: to reduce the risk of adverse effects while increasing the efficacy of TL01 phototherapy. Lesions should be sloughed before the start of phototherapy. Synergistic effects have been demonstrated for dermal corticosteroids and tazarotene, but such effects are less noticeable with topical vitamin D3 derivatives. If there are no contraindications to its prescription, we feel that acitretine has demonstrated efficacy in enhancing the effect of TL01 phototherapy. (4) Efficacy. Narrow-spectrum UVB phototherapy is considered highly effective in extensive psoriasis. At a rate of three sessions per week, it results in complete (or almost complete) eradication of lesions in 60 to 90 % of patients within 20 to 40 sessions (level of proof: A). However, the efficacy of this therapy varies according to plaque size and noticeably better results are obtained in guttate and nummular psoriasis than in psoriasis involving large plaques. CONCLUSION: Narrow-spectrum UVB phototherapy offers a good alternative to PUVA therapy since concomitant psoralen is not required, but there are few immediate adverse effects, there is less risk of drug-induced photosensitisation, and there is no need for skin or ocular photoprotection after sessions. We recommend this approach as the first-line phototherapy (level of proof: A) in children and adolescents, and in adults with extensive moderate psoriasis involving small superficial plaques. It may also be used in pregnant or breastfeeding women and in patients with renal or hepatic insufficiency. In addition, it is preferable for HIV-positive subjects (level of proof: C). However, PUVA therapy is preferable as first-line treatment in extensive severe psoriasis involving large thick plaques (level of proof: A) and in adults of phototypes IV to VI (level of proof: B); it should also be contemplated for psoriasis refractory to UVB TL01 (level of proof: B).
Assuntos
Psoríase/radioterapia , Terapia Ultravioleta/métodos , Adolescente , Adulto , Catarata/etiologia , Catarata/prevenção & controle , Criança , Terapia Combinada , Fármacos Dermatológicos/uso terapêutico , Dispositivos de Proteção dos Olhos , Feminino , Humanos , Masculino , Neoplasias Induzidas por Radiação/epidemiologia , Neoplasias Induzidas por Radiação/etiologia , Terapia PUVA , Gravidez , Complicações na Gravidez/radioterapia , Psoríase/tratamento farmacológico , Dosagem Radioterapêutica , Risco , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/etiologia , Terapia Ultravioleta/efeitos adversos , Terapia Ultravioleta/instrumentação , Terapia Ultravioleta/normasRESUMO
In this work the compliance of tanning lamps with technical standards EN 60335-2-27 'Household and similar electrical appliances-Safety. Part 2: Particular requirements for appliances for skin exposure to ultraviolet and infrared radiation' was analysed. Results of this analysis showed that none of the examined technical documentation produced by the lamps manufacturers is fully compliant with the standard technique. Furthermore data reported in the same manuals, such as effective radiant exposure or irradiance, would indicate that these sources may be the cause of undue exposure to ultraviolet (UV) radiation. For this reason a measurement campaign on UV lamps used in tanning salons was organised. The first results of these measurements seem to confirm the doubts raised from the analysis of the lamp manuals: the use of a tanning lamp can lead to UV radiation exposure levels higher than reference maximum values recommended by EN 60335-2-27.
Assuntos
Fidelidade a Diretrizes , Iluminação/instrumentação , Iluminação/normas , Radiometria/normas , Bronzeado , Terapia Ultravioleta/instrumentação , Terapia Ultravioleta/normas , Desenho de Equipamento , Análise de Falha de Equipamento , União Europeia , Guias como Assunto , Itália , Raios UltravioletaRESUMO
BACKGROUND: Very few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in Indian patients with vitiligo and are of small sample size. AIMS: The purpose of this study is to know the efficacy and safety of NBUVB in 150 vitiligo patients of various age groups. METHODS: One hundred fifty patients (69 males, 81 females), aged 3-70 years, with vitiligo were treated twice weekly with NBUVB. The starting dose was 250 mJ/cm2 in adults and 150 mJ/cm2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1 year and were followed-up for 6 months for stability of repigmentation. Statistical methods were employed to establish the relation between the response and the number of exposures, duration of treatment, cumulative dose and the compliance. RESULTS: Analysis of our study showed that a majority of our cases, about 73, achieved 25-75% repigmentation, with an average of 51+/-19 exposures, 51 had <25% repigmentation, with an average of 19+/-11 exposures and 26 had >75% repigmentation, with an average of 74+/-24 exposures. Good response to therapy was directly associated with good compliance, more number of exposures and increasing cumulative dose, which was statistically significant (P<0.01). Adverse effects were minimal. Only three patients developed depigmentation of repigmented sites during follow-up. CONCLUSION: Our study proves that NBUVB therapy is an effective and safe tool in the management of vitiligo, with good stability of repigmentation and cosmetic appearance.
Assuntos
Terapia Ultravioleta/métodos , Terapia Ultravioleta/normas , Vitiligo/radioterapia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Vitiligo/patologia , Adulto JovemRESUMO
The recently published German S3- guidelines for the treatment of psoriasis vulgaris offer an extensive evidence-based documentation and evaluation of currently available treatment modalities. In order to incorporate this detailed information into the actual treatment decisions in individual patients, we have transformed the recommendations regarding phototherapy and systemic therapies into an algorithm. This algorithm should allow a stepwise treatment approach in adult patients with moderate to severe psoriasis, in whom topical therapy is not sufficient. It can also facilitate documentation of treatment. In our hands the treatment algorithm proved to be feasible and reliable in a large number of patients.